The Motley Fool··Prosper Junior BakinyCRISPR Therapeutics Advances Gene-Editing Platform With First Approved Therapy
CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.
CRSPFDA approvalclinical trials